Location History:
- Glasgow, GB (2000)
- Strathclyde, GB (2009)
Company Filing History:
2 out of 150 
1 out of 168 
1 out of 591 
Years Active: 2000-2009
Title: The Innovative Contributions of Alan Lang Harvey
Introduction: Alan Lang Harvey, based in Strathclyde, GB, is a notable inventor recognized for his contributions to the field of pharmaceuticals. With a total of two patents to his name, he has made significant strides in developing innovative therapeutic agents that address various medical conditions.
Latest Patents: Among his latest patents, the "Par-2-activating peptide derivative and pharmaceutical composition using the same" stands out. This invention pertains to a peptide derivative represented by the general formula (I), which can be utilized as a prophylactic and therapeutic agent for numerous conditions. These include dysfunction of masticatory, dysphagia, dysgeusia, intra-oral cavity infections, dry eye, and various ulcerative diseases, among others. The composition also emphasizes the importance of a pharmaceutically acceptable carrier, highlighting its potential applications in enhancing patient outcomes.
Career Highlights: Alan has forged a reputable career through his associations with prestigious institutions such as the University of Strathclyde and the University of Edinburgh. His academic background has enabled him to focus on cutting-edge research and innovation in pharmaceuticals, significantly influencing both the academic and medical fields.
Collaborations: Throughout his career, Alan has collaborated with esteemed colleagues, including Robert Ramage and Robin Plevin. These collaborations have likely played a crucial role in the development of his patents, enriching the innovation process with shared knowledge and expertise.
Conclusion: Alan Lang Harvey exemplifies the impact of dedicated research and innovation in addressing complex health issues. His patents not only showcase his inventive capabilities but also reflect a broader commitment to improving patient care through scientific advancements. As he continues to work within the realms of pharmaceuticals, his contributions will likely influence future developments in the industry.